Management Tracks: Zealand, BeiGene
Zealand Pharma A/S (CSE:ZEAL; NASDAQ:ZEAL) said EVP and Chief Medical and Development Officer Adam Steensberg will become interim CEO on March 1. He will succeed Britt Meelby Jensen, who is leaving the company on Feb. 28. Zealand announced Meelby Jensen's resignation in November 2018. The company said it is interviewing candidates for the permanent CEO position.
The gastrointestinal and metabolic disease company also said Wednesday that CFO Mats Blom will leave at the end of March and that it has begun to search for a new CFO...